Figure 6.

Quantification of serum hsp60 and anti-hsp60 antibodies in patients with cancer associated retinopathy (CAR), autoimmune retinopathy (AR), and healthy subjects as controls. (A) Levels of circulating serum hsp60 in 20 AR patients and 20 controls; the mean concentration of hsp60 49.6 ± 9 ng · mL⁻¹ in control sera and 38.8 ± 10 ng · mL⁻¹ in AR sera; (B) Serum levels of human anti-hsp60 IgG/A/M in the cohort of 27 controls, 14 CAR, and 32 AR patients were measured by ELISA; Anti-hsp60 AAbs were significantly elevated levels of in CAR (2.24 ±0.13 ng · mL⁻¹) and AR sera (2.15 ± 0.10 ng · mL⁻¹) compared to healthy subjects (1.56 ± 0.06 ng · mL⁻¹; One-way ANOVA, p < 0.0001). The line represents the mean level for tested groups in A and B.